Mutations in the TP53 tumour suppressor gene are very frequent in cancer, and attempts to
restore the functionality of p53 in tumours as a therapeutic strategy began decades ago …

The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …

Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Abstract p53, encoded by the tumor suppressor gene TP53, is one of the most important
tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53 …

Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2
represents an attractive treatment approach for cancers with wild-type or functional TP53 …

Cellular senescence is a permanent state of cell cycle arrest that occurs in proliferating cells
subjected to different stresses. Senescence is, therefore, a cellular defense mechanism that …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

The last 40 years have witnessed how p53 rose from a viral binding protein to a central
factor in both stress responses and tumor suppression. The exquisite regulation of p53 …

Pharmaceutical research has successfully incorporated a wealth of molecular modeling
methods, within a variety of drug discovery programs, to study complex biological and …